Gilead Sciences annual asset turnover
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Asset Turnover Growth & History (GILD)
Gilead Sciences's asset turnover was 0.50 for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.50 | 0.02 | +5.09% |
| 2024 | 2024-12-31 | 0.47 | 0.04 | +9.70% |
| 2023 | 2023-12-31 | 0.43 | 0.02 | +4.02% |
| 2022 | 2022-12-31 | 0.42 | 0.02 | +3.90% |
| 2021 | 2021-12-31 | 0.40 | 0.02 | +5.47% |
| 2020 | 2020-12-31 | 0.38 | 0.02 | +5.98% |
| 2019 | 2019-12-31 | 0.36 | 0.03 | +8.46% |
| 2018 | 2018-12-31 | 0.33 | −0.08 | −19.48% |
| 2017 | 2017-12-31 | 0.41 | −0.15 | −26.63% |
| 2016 | 2016-12-31 | 0.56 | −0.20 | −26.00% |
| 2015 | 2015-12-31 | 0.76 | −0.11 | −13.10% |
| 2014 | 2014-12-31 | 0.87 | 0.36 | +70.09% |
| 2013 | 2013-12-31 | 0.51 | 0.01 | +1.55% |
| 2012 | 2012-12-31 | 0.50 | −0.08 | −13.25% |
| 2011 | 2011-12-31 | 0.58 | −0.17 | −22.28% |
| 2010 | 2010-12-31 | 0.75 | −0.10 | −11.41% |
| 2009 | 2009-12-31 | 0.84 | — | — |
Gilead Sciences quarterly asset turnover
Q1.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Asset turnover | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.58 | 0.05 | +9.76% |
| Q1 2026 | 2026-03-31 | 0.53 | 0.02 | +3.50% |
| Q4 2025 | 2025-12-31 | 0.50 | 0.02 | +5.09% |
| Q3 2025 | 2025-09-30 | 0.51 | 0.03 | +6.28% |
| Q2 2025 | 2025-06-30 | 0.53 | 0.05 | +10.09% |
| Q1 2025 | 2025-03-31 | 0.51 | 0.05 | +9.73% |
| Q4 2024 | 2024-12-31 | 0.47 | 0.04 | +9.70% |
| Q3 2024 | 2024-09-30 | 0.48 | 0.05 | +10.41% |
| Q2 2024 | 2024-06-30 | 0.48 | 0.04 | +9.68% |
| Q1 2024 | 2024-03-31 | 0.46 | 0.03 | +7.34% |
| Q4 2023 | 2023-12-31 | 0.43 | 0.02 | +4.02% |
| Q3 2023 | 2023-09-30 | 0.44 | 0.02 | +4.76% |
| Q2 2023 | 2023-06-30 | 0.44 | 0.02 | +4.00% |
| Q1 2023 | 2023-03-31 | 0.43 | 0.01 | +2.86% |
| Q4 2022 | 2022-12-31 | 0.42 | 0.02 | +3.90% |
| Q3 2022 | 2022-09-30 | 0.42 | −0.01 | −2.54% |
| Q2 2022 | 2022-06-30 | 0.42 | −0.01 | −2.18% |
| Q1 2022 | 2022-03-31 | 0.42 | 0.02 | +4.72% |
| Q4 2021 | 2021-12-31 | 0.40 | 0.02 | +5.47% |
| Q3 2021 | 2021-09-30 | 0.43 | 0.04 | +11.35% |
| Q2 2021 | 2021-06-30 | 0.43 | 0.06 | +15.50% |
| Q1 2021 | 2021-03-31 | 0.40 | 0.03 | +8.42% |
| Q4 2020 | 2020-12-31 | 0.38 | 0.02 | +5.98% |
| Q3 2020 | 2020-09-30 | 0.39 | 0.02 | +6.45% |
| Q2 2020 | 2020-06-30 | 0.37 | 0.02 | +7.02% |
| Q1 2020 | 2020-03-31 | 0.37 | 0.02 | +6.46% |
| Q4 2019 | 2019-12-31 | 0.36 | 0.03 | +8.46% |
| Q3 2019 | 2019-09-30 | 0.36 | 0.02 | +4.86% |
| Q2 2019 | 2019-06-30 | 0.35 | −0.02 | −5.83% |
| Q1 2019 | 2019-03-31 | 0.35 | −0.05 | −13.22% |
| Q4 2018 | 2018-12-31 | 0.33 | −0.08 | −19.48% |
| Q3 2018 | 2018-09-30 | 0.35 | −0.11 | −23.75% |
| Q2 2018 | 2018-06-30 | 0.37 | −0.15 | −28.48% |
| Q1 2018 | 2018-03-31 | 0.40 | −0.15 | −27.30% |
| Q4 2017 | 2017-12-31 | 0.41 | −0.15 | −26.63% |
| Q3 2017 | 2017-09-30 | 0.45 | −0.14 | −23.04% |
| Q2 2017 | 2017-06-30 | 0.52 | −0.21 | −28.89% |
| Q1 2017 | 2017-03-31 | 0.55 | −0.21 | −27.67% |
| Q4 2016 | 2016-12-31 | 0.56 | −0.20 | −26.00% |
| Q3 2016 | 2016-09-30 | 0.59 | −0.20 | −25.58% |
| Q2 2016 | 2016-06-30 | 0.73 | −0.10 | −12.47% |
| Q1 2016 | 2016-03-31 | 0.76 | −0.06 | −7.84% |
| Q4 2015 | 2015-12-31 | 0.76 | −0.11 | −13.10% |
| Q3 2015 | 2015-09-30 | 0.79 | −0.02 | −1.90% |
| Q2 2015 | 2015-06-30 | 0.83 | 0.18 | +28.07% |
| Q1 2015 | 2015-03-31 | 0.83 | 0.28 | +52.29% |
| Q4 2014 | 2014-12-31 | 0.87 | 0.36 | +70.09% |
| Q3 2014 | 2014-09-30 | 0.81 | 0.32 | +64.17% |
| Q2 2014 | 2014-06-30 | 0.65 | 0.17 | +35.44% |
| Q1 2014 | 2014-03-31 | 0.54 | 0.07 | +15.16% |
| Q4 2013 | 2013-12-31 | 0.51 | 0.01 | +1.55% |
| Q3 2013 | 2013-09-30 | 0.49 | −0.06 | −11.37% |
| Q2 2013 | 2013-06-30 | 0.48 | −0.06 | −11.88% |
| Q1 2013 | 2013-03-31 | 0.47 | −0.06 | −11.07% |
| Q4 2012 | 2012-12-31 | 0.50 | −0.08 | −13.25% |
| Q3 2012 | 2012-09-30 | 0.55 | −0.12 | −18.39% |
| Q2 2012 | 2012-06-30 | 0.54 | −0.14 | −20.64% |
| Q1 2012 | 2012-03-31 | 0.53 | −0.16 | −22.71% |
| Q4 2011 | 2011-12-31 | 0.58 | −0.19 | −25.06% |
| Q3 2011 | 2011-09-30 | 0.68 | −0.13 | −15.58% |
| Q2 2011 | 2011-06-30 | 0.68 | — | — |
| Q1 2011 | 2011-03-31 | 0.69 | −0.17 | −19.98% |
| Q4 2010 | 2010-12-31 | 0.77 | — | — |
| Q3 2010 | 2010-09-30 | 0.80 | — | — |
| Q1 2010 | 2010-03-31 | 0.86 | — | — |
Gilead Sciences asset turnover trends
Over the last five fiscal years, Gilead Sciences's asset turnover increased from 0.38 to 0.50, a change of 0.12. The latest reported quarter, Q2 2026, shows 0.58.
About the metric
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
Calculation and source
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
